This is a material clinical validation of Zymeworks' ADC platform and significantly de-risks ZW191's development path. Traders should monitor upcoming Part 2a data for dose selection and potential partnership announcements, which could catalyze further upside. The broad activity across FRα expression levels increases commercial addressability.
Price Chart
Executive Summary
Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed objective response rate in platinum-resistant ovarian cancer at doses of 6.4–9.6 mg/kg, with durable responses and a manageable safety profile. The data support advancing ZW191 into later-stage development for ovarian and endometrial cancers, where treatment options are limited.
Key Facts
- ZW191 showed a 61% confirmed objective response rate (cORR) in platinum-resistant ovarian cancer at 6.4–9.6 mg/kg dose range.
- Median progression-free survival was 7.6 months; median duration of response not reached, indicating durability.
- Activity was observed regardless of FRα expression, expanding potential patient population.
- Safety profile was manageable, with 55% grade ≥3 treatment-emergent adverse events (mostly neutropenia, anemia, thrombocytopenia).
- Part 2a of the trial (dose optimization) has completed enrollment; data will inform registration-enabling studies.
Financial Impact
Potential blockbuster value if ZW191 advances successfully — addresses large unmet need in ovarian and endometrial cancers with strong early efficacy.
Risk Factors
- Phase 1 data are early and from a small cohort; efficacy may not hold in larger trials.
- Safety concerns around neutropenia and anemia could limit dosing or require supportive care, affecting adoption.
- Competitive ADCs in FRα space (e.g., Elahere) may create market headwinds despite broader activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278571 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.18 (−8.32%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.18 (−4.11%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.18 (+4.50%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.18 (+8.28%) |
May 15, 2026 19w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.18 (+3.09%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.18 (−11.72%) |
Apr 17, 2026 23w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.18 (−9.41%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.18 (−7.41%) |
Apr 10, 2026 24w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.18 (−3.76%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.18 (+7.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access